Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma

NCT06370871 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor decision.

Conditions

Advanced Soft Tissue Sarcoma
Undifferentiated Pleomorphic Sarcoma (UPS)
Myxofibrosarcoma (MFS)

Interventions

DRUG: Brigimadlin
DRUG: Ezabenlimab
DRUG: Gemcitabine
DRUG: Docetaxel

Sponsor

Boehringer Ingelheim